[ad_1]
The increase in cases of skin diseases contributes to the need for drug approval and organic medicines.
FORT COLLINS, Colo., March 14, 2024 (Globe Newswire) — The atopic dermatitis market size was valued at $9.1 billion in 2023 and is expected to reach a market size of $18.6 billion by 2032, at a CAGR of 8.3%.
Atopic dermatitis, commonly known as eczema, is a chronic inflammatory skin disease characterized by itching, redness, swelling, and cracking of the skin. The increasing prevalence of atopic dermatitis can be attributed to a variety of factors, including genetic predisposition, environmental influences, and lifestyle choices. This increase in global penetration is expected to drive market growth during the forecast period. For example, according to a report by the International Federation of Dermatological Societies (ILDS), approximately 223 million people will have atopic dermatitis in 2022, of which approximately 43 million will be in the age range of 1 to 4 years. .
Increased number of products approved for treatment atopic dermatitis Reflects advances in important medical research and pharmaceutical innovation. New treatments such as topical creams, oral medications, and biological therapies offer a wide range of options for managing symptoms. With the wide availability of effective treatments, people with atopic dermatitis are more likely to seek medical help and receive appropriate treatment, resulting in improved diagnosis rates. .
For example, in June 2022, pharmaceutical company Sanofi launched Dupixent, which was approved by the U.S. Food and Drug Administration. Dupixent (dupilumab) is primarily indicated for children 6 months to 5 years of age with moderate to severe atopic dermatitis that is inadequately controlled by topical prescription therapy or for which such therapy is not recommended. .
Request a sample report:
https://bit.ly/3VjOYsU
Segmentation overview:
global Atopic dermatitis market is subdivided into Drug class, route of administration, age group, region. Based on drug class, the market segmentation consists of corticosteroids, calcineurin inhibitors, PDE4 inhibitors, biologics, etc. Corticosteroids are expected to dominate the market growth during the forecast period due to their anti-inflammatory properties. Based on route of administration, the market is further segmented into topical, oral, and injection. Injectables are expected to register significant growth in 2023 and dominate the market growth during the forecast period due to increasing approvals of injectables such as dupilumab. This monoclonal antibody targets interleukin-4 receptor alpha, reducing inflammation and symptoms.
Purchase this research report:
https://bit.ly/3IzfZRk
Highlights of the atopic dermatitis market report:
-
Atopic dermatitis is mainly used in the petrochemical, pharmaceutical and chemical industries to prevent quality deterioration and raw material waste.
-
The North American pharmaceutical industry relies on pneumatic conveyor systems to transport powders and granules in a pollution-free environment, ensuring the quality and purity of pharmaceutical products.
-
Notable players in the atopic dermatitis market report include Atlas Copco AB, Coperion GmbH, Cyclonaire Corporation, Dongyang P&F, Dynamic Air Inc., Flexicon Corporation, Gericke AG, VAC-U-MAX, Schenck Process Holding GmbH, Pneumatic Conveying , Inc., Nol-Tec Systems Inc., Nilfisk Group, Gericke AG.
Industry trends and insights:
– The United States Food and Drug Administration (USFDA) and the European Medicines Agency (EMA) play important roles in the approval and regulation of medicines. Authorities are working to streamline the approval process for innovative treatments, with an emphasis on patient safety.
– The prevalence of atopic dermatitis is higher in developed countries. In developing countries, the incidence of atopic dermatitis is increasing due to changes in lifestyle, socio-economic factors, and climate change.
– This condition is common in children for unspecified reasons. However, the incidence is also high in adults.
Looking for region/country-specific reports only?
https://bit.ly/3Vfb93e
or
ask for discount
https://bit.ly/43ew6gJ
Atopic dermatitis market segmentation:
By drug class: Corticosteroids, calcineurin inhibitors, PDE4 inhibitors, biologics, etc.
By route of administration: Topical, oral, injection
By age group: children and adults
By region: North America, Latin America, Europe, Asia Pacific, Middle East and Africa.
About DataHorizon Research:
DataHorizon is a market research and advisory firm that helps organizations around the world develop growth strategies that align with changing business dynamics. Its services include enterprise-wide consulting services and business insights to make actionable decisions. DHR’s comprehensive research methodology for predicting long-term, sustainable market trends makes complex decision-making easier for organizations.
contact:
Post: sales@datahorizzonresearch.com
Doctor: +1-970-672-0390
Website: https://datahorizonresearch.com/
Please follow us: linkedin
Recent publications:
Healthcare predictive analytics market
Implantable medical device market
Over-the-counter (OTC) drug market
drug discovery market
Targeted DNA RNA Sequencing Market
CONTACT: Mail: sales@datahorizzonresearch.com Ph: +1-970-672-0390 Website: https://www.datahorizzonresearch.com
[ad_2]
Source link
